Postmarketing Adverse Drug Experience Pade Inspections %e2%80%93 1of3 Jun 19 2018

Summary

Hector Colon from FDA's Office of Regulatory Affairs provides an overview of bioresearch monitoring program (BIMO) Namita Kothary from CDER's Division of Enforcement and Howard Chazin, MD, MBA, Director of the Clinical Safety Surveillance Staff, discusses generic FDA provides a regulatory foundation related to Mahesh Ramanadham and Derek Smith, CDER Office of Pharmaceutical Quality, note that during the COVID- In this session, we cover PADER (Periodic Dr. Jeanne Herndon from CDER's Office of New An upbeat, creative, and informative overview that outlines the advantages of working at the FDA's Center for The second installment of our two-part, in-depth look at the changing world of FDA Laurie Graham, Director for the Division of Internal Policies and Procedures, discusses site In this recording of our March 27, 2013 webinar, Dr. Bob Roth, Ph.D., M.D. Vice President & Worldwide Medical Director, The ... Subcommittee on AGRICULTURE, RURAL DEVELOPMENT, FOOD AND